IFNγ score-based neoadjuvant immunotherapy for stage III melanoma.

ABSTRACT: In this issue of JEM, Reijers et al. (2023. J. Exp. Med.https://doi.org/10.1084/jem.20221952) demonstrate that pre- and post-treatment IFNγ-related gene expression scores are promising markers for choosing neoadjuvant immunotherapy for stage III melanoma.

SUBMITTER: Fukuda K 

PROVIDER: S-EPMC10035434 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature